ArticleKidney international reports2018
mTORC1 Inhibition Is an Effective Treatment for Sporadic Renal Angiomyolipoma.
Article in Kidney international reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Complication Rates and Effectiveness of Renal Angiomyolipoma Embolisation: A Systematic Review and Meta-analysis.Cardiovascular and interventional radiology · 2026Pooled it
- Long-term follow-up monitoring with multimodal ultrasound in a case of suspected renal angiomyolipoma with renal vein/inferior vena cava thrombus: a case report.BMC nephrology · 2026Article
- Case Report: mTOR inhibitor treatment for epithelioid angiomyolipoma harboring biallelicFrontiers in oncology · 2026Article
- Renal epithelioid angiomyolipomas overexpress TFE3 and the TFE3-regulated gene TRIM63 in the absence of TFE3 rearrangement.Virchows Archiv : an international journal of pathology · 2024Article
- Effectiveness of everolimus for sporadic renal angiomyolipoma with inferior vena cava thrombus: A case report.Urology case reports · 2023Article
- An Israeli tuberous sclerosis cohort: the efficacy of different anti-epileptic strategies.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2021Article
- Sporadic, classic-type renal angiomyolipoma with renal vein and inferior vena cava extension: an incidental case.BMJ case reports · 2021Article
- Renal Manifestations of Tuberous Sclerosis Complex.Journal of kidney cancer and VHL · 2020Review
- Retroperitoneal perivascular epithelioid cell tumours: A case report and review of literature.World journal of clinical cases · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRenal angiomyolipoma (AML) is the most common benign renal tumor. Despite a generally benign histology, AML can result in significant morbidity, from intra-abdominal hemorrhage and reduction in kidney function. While classically associated with the autosomal dominant disorder tuberous sclerosis complex (TSC) or with pulmonary lymphangioleiomyomatosis, most AMLs are sporadic. Mammalian target of rapamycin complex 1 (mTORC1) inhibitors (e.g., sirolimus) have been found to be effective in treating TSC- or lymphangioleiomyomatosis-associated AML, but to date it is unknown whether this strategy is effective for sporadic AML.
methodsWe stained tumor specimens of sporadic AML patients for pS6 to assess for mTORC1 activation.
resultsWe detected strong activation of the mTORC1 pathway, similar to TSC-associated AML. Consequently, we showed that
conclusionWe propose mTORC1 inhibition as an effective treatment option for patients with sporadic AML, which represents the vast majority of patients with this tumor.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.